product name Streptozotocin (STZ)
Description: Streptozotocin (also known as NSC-85998, STZ) is a glucosamine-nitrosourea derivative, which is a methylating, carcinogenic, antibiotic and diabetes inducing agent. Streptozocin is a methylnitrosourea antineoplastic antibiotic isolated from the bacterium Streptomyces achromogenes. Streptozocin alkylates DNA, forming inter-strand DNA cross-links and inhibiting DNA synthesis. Due to its glucose moiety, this agent is readily taken up by pancreatic beta cells, inducing diabetes mellitus at high concentrations.
References: Mutat Res. 2002;512:121-34; Biochem Mol Biol Int. 1996;39(6):1229-36; Diabetes. 1967;16(1):51-6.
265.22
Formula
C8H15N3O7
CAS No.
18883-66-4
Storage
-20℃ for 3 years in powder form
-80℃ for 2 years in solvent
Solubility (In vitro)
DMSO: 53 mg/mL (199.8 mM)
Water: 53 mg/mL (199.8 mM)
Ethanol: <1 mg/mL
Solubility (In vivo)
Saline: 30 mg/mL
Synonyms
NSC-85998
other peoduct :
| In Vitro |
In vitro activity: Streptozotocin directly methylates DNA and is highly genotoxic, producing DNA strand breaks, alkali-labile sites, unscheduled DNA synthesis, DNA adducts, chromosomal aberrations, micronuclei, sister chromatid exchanges, and cell death. Free radicals are involved in the production of DNA and chromosome damage by Streptozotocin. Streptozotocin is toxic to pancreatic beta cell. Exposed to 15 mM Streptozotocin for 1 hr followed by a 24 hrs recovery period induces apoptosis in murine pancreatic beta cell line, INS-1. Streptozotocin (30 mM) causes the cells to undergo necrosis (22%) as well as apoptosis (17%). Kinase Assay: Cell Assay: |
|---|---|
| In Vivo | Streptozotocin is often used to induce diabetes mellitus in experimental animals. Streptozotocin is selectively accumulated in pancreatic beta cells via the low-affinity GLUT 2 glucose transporter. Streptozotocin (60 mg/kg) injection for 4 month induces rapid degranulation of beta cells without necrosis, development of cataracts and accumulation of glycogen in the proximal convoluted tubules of the kidney. Streptozotocin (100 mg/kg) produces lesions in the exocrine cells of the pancreas, and persistence of small, possibly secretory, granules in the Golgi zone of beta cells in rats of ‘Streptozotocin diabetes’. Streptozotocin is found to be carcinogenic in rats, mice and hamster. A single administration of Streptozotocin is able to induce tumors in kidney, liver, lung, pancreas, uterine and liver tumors in hamster. Intraperitoneally injected with Streptozotocin (100-150 mg/kg) for normotensive Wistar Kyoto rats (WKY) for 12 months induces carcinogenesis with tumors incidence of 70% in liver, 20% in kidney and 10% in liver and kidney. |
| Animal model | |
| Formulation & Dosage | |
| References | Mutat Res. 2002 Dec;512(2-3):121-34; Biochem Mol Biol Int. 1996 Aug;39(6):1229-36; Diabetes. 1967 Jan;16(1):51-6. |
